Market Research Logo

Global Peptide Therapeutics Market 2016-2020

Global Peptide Therapeutics Market 2016-2020

About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

Technavio’s analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
Other prominent vendors
  • AbbVie
  • Advanced Accelerator Applications
  • Akashi Therapeutics
  • Amgen
  • Anthera Pharmaceuticals
  • AstraZeneca
  • Bachem
  • Bristol-Myers Squibb
  • Cardiorentis
  • Corden Pharma International
  • Debiopharm
  • Derma Sciences
  • GlaxoSmithKline
  • Hanmi Pharmaceutical
  • Insmed
  • Ipsen
  • Johnson & Johnson
  • Lonza
  • Mallinckrodt
  • MolMed
  • Merck
  • Novartis
  • Nymox Pharmaceutical
  • Par Pharmaceuticals
  • PeptiDream
  • Polypeptide Group
  • Radius Health
  • Repligen
  • Roche
  • SciClone
  • Shire
  • The Medicines Company
  • Transition Therapeutics
  • X-Gen Pharmaceuticals
  • Zealand Pharma
  • Zydus Cadila
Market driver
  • Increase in patient population
  • For a full, detailed list, view our report
Market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Market trend
  • Shifting focus toward untapped markets
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Peptide Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Peptide Therapeutics Market: Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, and Teva Pharmaceuticals.

Other Prominent Vendors in the market are: AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “The recent shift towards untapped markets is another critical factor that will impel market growth during the forecast period. Recently, it has been observed that vendors of peptide therapeutics are moving to developing economies due to the presence of large population groups and clinical trial subjects.”

According to the report, recent advances in peptide synthesis technology will be the key driver for the growth of this market. Among all the methods of peptide synthesis, chemical and enzymatic syntheses are the most important. The synthesis of peptides has integrated structure-activity relationships (SARs) and analog generations to increase bioavailability, reduce adverse effects, increase the safety and efficacy of drugs, impart protease resistance, and develop formulations.

Further, the report states that the high cost of therapy; however, will hinder the market growth. As peptide drugs are expensive, few people opt for this mode of treatment.

Companies Mentioned

Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, Teva Pharmaceuticals, AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, Zydus Cadila.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Overview of peptides
    • Table SWOT analysis: Peptide therapeutics
    • Peptide synthesis
      • Table Steps involved in peptide synthesis
    • Optimization of peptides
      • Table Optimization of peptide synthesis
    • Stabilization of peptides
      • Table Methods used to stabilize peptides
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global peptide therapeutics market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation based on route of administration
    • Table Global peptide therapeutics market segmentation based on route of administration
    • Parenteral
    • Oral
    • Pulmonary
    • Mucosal
      • Table Global peptide therapeutics market segmentation by route of administration 2015
  • Market segmentation by drug class
    • Table Global peptide therapeutics market segmentation by drug class
    • Somatostatins
    • Vasopressin
    • Calcitonins
    • Luteinizing hormone (LH)-releasing hormone (LHRH)
    • Glucagon and analogs
    • Insulins
    • Other
  • Market segmentation by synthesis technology
    • Table Global peptide therapeutics market segmentation by synthesis technology
    • Liquid-phase peptide synthesis
    • Solid-phase peptide synthesis
    • Hybrid peptide synthesis
  • Geographical segmentation
    • Global peptide therapeutics market segmentation by geography 2015-2020
      • Table Global peptide therapeutics market segmentation by geography 2015
      • Table Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
    • Peptide therapeutics market in Americas
      • Table Peptide therapeutics market in Americas 2015-2020 ($ billions)
    • Peptide therapeutics market in EMEA
      • Table Peptide therapeutics market in EMEA 2015-2020 ($ billions)
    • Peptide therapeutics market in APAC
      • Table Peptide therapeutics market in APAC 2015-2020 ($ billions)
      • Table Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in patient population
    • Advances in peptide synthesis technology
    • Promising pipeline
    • Unmet medical needs
    • Increase in healthcare spending
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of therapy
    • Adverse side effects
    • Stringent regulatory compliances
    • Intense market competition
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Growing popularity
    • Shifting focus toward untapped markets
    • Contract manufacturing
    • Increase in public awareness
  • Vendor landscape
    • Competitive scenario
    • Eli Lilly
      • Table El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
      • Table Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
      • Table Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
      • Table Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
      • Table Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
      • Table Eli Lilly: Key takeaways
    • Novo Nordisk
      • Table Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of NovoLog 2014
      • Table Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of NovoMix 2014
      • Table Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of Norditropin 2014
      • Table Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
      • Table Novo Nordisk: Geographical split of revenues of Prandin 2014
      • Table Novo Nordisk: Key takeaways
    • Sanofi
      • Table Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
      • Table Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
      • Table Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
      • Table Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
      • Table Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
      • Table Sanofi: Key takeaways
    • Takeda Pharmaceutical
      • Table Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
      • Table Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
      • Table Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
      • Table Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
      • Table Takeda Pharmaceutical: Key takeaways
    • Teva Pharmaceuticals
      • Table Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
      • Table Teva Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report